Retour à la liste des essais cliniquesCancers urogénitaux

CAAA617D12302

A prospective, multicenter, open-label, randomized international Phase III study evaluating treatment with lutetium (177Lu) vipivotide tetraxetan (AAA617) versus surveillance alone to delay the need for castration or disease recurrence in adult male patients with PSMA-positive oligometastatic prostate cancer.

Ouvert à Paris depuis le : 26/07/2024
Ouvert à Saint-Cloud depuis le : 26/07/2024
Public cible : Adult
Phase : Phase III

Description de l'essai

The primary objective of this study is to address the following question: Is the AAA617 treatment effective in delaying the progression of prostate cancer?

Url of the trial

Investigateur principal

CAPUCINE RICHARD

Médecin

Contacter